MX2013003162A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013003162A
MX2013003162A MX2013003162A MX2013003162A MX2013003162A MX 2013003162 A MX2013003162 A MX 2013003162A MX 2013003162 A MX2013003162 A MX 2013003162A MX 2013003162 A MX2013003162 A MX 2013003162A MX 2013003162 A MX2013003162 A MX 2013003162A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
subjects
formula
treatment
methods
Prior art date
Application number
MX2013003162A
Other languages
English (en)
Inventor
Mark Spyvee
Takashi Satoh
Jonathan Eric Carlson
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2013003162A publication Critical patent/MX2013003162A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención provee compuestos de fórmula (I): (Ver formula) junto con composiciones farmacéuticas que contienen los mismos, y métodos de uso de los mismos en sujetos en necesidad de tratamiento.
MX2013003162A 2010-09-21 2011-09-12 Composicion farmaceutica. MX2013003162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013003162A true MX2013003162A (es) 2013-05-06

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003162A MX2013003162A (es) 2010-09-21 2011-09-12 Composicion farmaceutica.

Country Status (30)

Country Link
US (2) US8686018B2 (es)
EP (2) EP3061751A1 (es)
JP (1) JP5956448B2 (es)
KR (1) KR101911105B1 (es)
CN (1) CN103097358B (es)
AU (1) AU2011305872B2 (es)
BR (1) BR112013002484B1 (es)
CA (1) CA2806121C (es)
CL (1) CL2013000675A1 (es)
CY (1) CY1118680T1 (es)
DK (1) DK2619182T3 (es)
ES (1) ES2610185T3 (es)
HR (1) HRP20170042T1 (es)
HU (1) HUE031408T2 (es)
IL (1) IL224288A (es)
LT (1) LT2619182T (es)
ME (1) ME02575B (es)
MX (1) MX2013003162A (es)
MY (1) MY162146A (es)
NZ (1) NZ606629A (es)
PE (1) PE20131343A1 (es)
PL (1) PL2619182T3 (es)
PT (1) PT2619182T (es)
RS (1) RS55566B1 (es)
RU (1) RU2606510C2 (es)
SG (1) SG188188A1 (es)
SI (1) SI2619182T1 (es)
SM (1) SMT201700008B (es)
UA (1) UA113499C2 (es)
WO (1) WO2012039972A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
HUE039015T2 (hu) * 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US20170182003A1 (en) * 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
US20230125494A1 (en) * 2020-03-04 2023-04-27 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Synthesis of novel ep4 antagonist and use in cancer and inflammation
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
TW202227089A (zh) 2020-11-30 2022-07-16 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
WO2022161418A1 (zh) * 2021-01-28 2022-08-04 深圳晶泰科技有限公司 吡唑酰胺衍生物及其制备方法和应用
WO2023030492A1 (zh) * 2021-09-03 2023-03-09 武汉人福创新药物研发中心有限公司 一种ep4拮抗剂化合物及其盐、多晶型和用途
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
WO2023122289A1 (en) 2021-12-23 2023-06-29 Eisai R&D Management Co., Ltd. Crystalline salt form of ep4 antagonist
WO2023125724A1 (zh) * 2021-12-30 2023-07-06 杭州阿诺生物医药科技有限公司 一种固体药物组合物
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
JP4838121B2 (ja) * 2003-06-26 2011-12-14 ノバルティス アーゲー ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤
BRPI0414130B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
GT200500013A (es) 2004-01-23 2005-08-10 Amidas herbicidas
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
WO2005105733A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2006134318A1 (en) * 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
US7994204B2 (en) * 2006-02-06 2011-08-09 Taisho Pharmaceutical Co., Ltd Binding inhibitor of sphingosine-1-phosphate
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
US8969394B2 (en) 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
CA2672631A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
ES2369215T3 (es) 2007-06-15 2011-11-28 Basf Se Procedimiento para la obtención de compuestos de pirazol substituidos con difluormetilo.
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
NZ582057A (en) 2007-07-19 2012-03-30 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
CL2008002241A1 (es) 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
PL2310360T3 (pl) 2008-08-01 2013-07-31 Bayer Ip Gmbh Grzybobójcze pochodne N-cykloalkilo-N-bifenylometylo-karboksamidu
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists

Also Published As

Publication number Publication date
JP2013538825A (ja) 2013-10-17
CL2013000675A1 (es) 2013-07-05
US9000024B2 (en) 2015-04-07
BR112013002484B1 (pt) 2021-10-13
KR101911105B1 (ko) 2018-10-23
KR20130099008A (ko) 2013-09-05
CN103097358B (zh) 2015-04-08
JP5956448B2 (ja) 2016-07-27
RU2606510C2 (ru) 2017-01-10
ME02575B (me) 2017-06-20
US8686018B2 (en) 2014-04-01
RU2013118209A (ru) 2014-10-27
HRP20170042T1 (hr) 2017-03-10
NZ606629A (en) 2015-03-27
BR112013002484A2 (pt) 2016-05-31
EP2619182A1 (en) 2013-07-31
LT2619182T (lt) 2017-01-25
AU2011305872A1 (en) 2013-01-31
WO2012039972A1 (en) 2012-03-29
ES2610185T3 (es) 2017-04-26
CY1118680T1 (el) 2017-07-12
US20140155452A1 (en) 2014-06-05
SI2619182T1 (sl) 2017-03-31
DK2619182T3 (en) 2017-01-30
PE20131343A1 (es) 2013-11-18
HUE031408T2 (en) 2017-07-28
EP2619182B1 (en) 2016-11-09
CN103097358A (zh) 2013-05-08
MY162146A (en) 2017-05-31
SG188188A1 (en) 2013-04-30
UA113499C2 (xx) 2017-02-10
IL224288A (en) 2015-02-26
CA2806121C (en) 2018-10-09
PL2619182T3 (pl) 2017-03-31
CA2806121A1 (en) 2012-03-29
EP3061751A1 (en) 2016-08-31
SMT201700008B (it) 2017-03-08
US20130237578A1 (en) 2013-09-12
RS55566B1 (sr) 2017-05-31
AU2011305872B2 (en) 2015-03-26
PT2619182T (pt) 2017-01-17

Similar Documents

Publication Publication Date Title
MY162146A (en) Pharmaceutical composition
PH12015500825A1 (en) Substituted benzene compounds
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2013011922A (es) Compuestos de benceno substituido.
PH12015501609A1 (en) Phenicol antibacterials
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
IN2015DN01156A (es)
PH12015501385A1 (en) Autotaxin inhibitors
MY153915A (en) Organic compounds
GB201106750D0 (en) Novel compounds
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201370018A1 (ru) Составы рифаксимина и их применение
MX2013004061A (es) Analogos de ciclosporina.
MX342947B (es) Tratamiento de diabetes tipo 2.
SG158091A1 (en) Imidazoazepinone compounds
MX2013004062A (es) Analogos de ciclosporina.
IN2015DN02109A (es)
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EP2563785A4 (en) Compounds as Agonists Against S1P1 Receptors
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
TN2010000583A1 (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration